Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 2844 • 2015 ACR/ARHP Annual Meeting
Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies
Alice B. Gottlieb¹, Kristian Reich², Zailong Wang³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Dermatologikum Hamburg and Georg-August-University Göttingen, Hamburg, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Nail psoriasis is associated with decreased finger mobility and pain in patients (pts) with moderate to severe plaque psoriasis and psoriatic arthritis (PsA).1,2 Secukinumab,…
Abstract Number: 2853 • 2015 ACR/ARHP Annual Meeting
Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial
Alice B. Gottlieb¹, Diamant Thaci², Andrew Blauvelt³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ²Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ³Research Excellence & Personalized Patient Care, Oregon Medical Research Center, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) is a common comorbidity in patients (pts) with psoriasis. In the ongoing Phase 3b CLEAR study (NCT02074982), secukinumab, a fully human…
Abstract Number: 3163 • 2015 ACR/ARHP Annual Meeting
The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Uyen Sa D.T. Nguyen¹, Yuqing Zhang², Na Lu³, Qiong Louie-Gao⁴, Jingbo Niu⁵, David T. Felson⁵, Michael P. Lavalley⁶, Thorvardur Love^7,8, Maureen Dubreuil⁴, Jeffrey A. Sparks⁹, Elizabeth W. Karlson¹⁰ and Hyon K. Choi³, ¹Orthopedics & Physical Rehabilation, Univerity of Massachusetts Medical School, Worcester, MA, ²Clinical Epidemilogy and Training Unit, Boston University School of Medicine, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁶Biostatistics, Boston University, Boston, MA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ¹⁰Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Smoking is a strong risk factor of psoriasis, but a previous study has suggested that smoking protects against the development of psoriatic arthritis (PsA)…
Abstract Number: 660 • 2015 ACR/ARHP Annual Meeting
Comparison of the Four Validated Psoriatic Arthritis Screening Tools in Diagnosing Psoriatic Arthritis in Patients with Psoriasis [Compaq Study]
Aman Sharma¹, Sushant Mishra², Sunil Dogra³ and Harish Kancharla², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Internal Medicine,, PGIMER,, Chandigarh, India, ³Department of Dermatology, PGIMER,, Chandigarh, India
Background/Purpose: Although there are various Psoriatic arthritis (PsA) screening questionnaires, the most optimal screening instrument is not known. The objective of the present study was…
Abstract Number: 673 • 2015 ACR/ARHP Annual Meeting
Characterization of Psoriatic Arthritis [Psa] in a Large, Integrated Health Plan: Demographics, Referral Patterns and Care Management
Vibeke Strand¹, Melody Chin², Arijit Ganguli³, Ridhima Nerlekar⁴, Victoria Kelly⁵, Daniel Chin⁶ and Alice Pressman⁴, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²University of California, San Francisco, San Francisco, CA, ³AbbVie Inc., North Chicago, IL, ⁴Research, Development, and Dissemination, Sutter Health, Walnut Creek, CA, ⁵Rheumatology, Palo Alto Medical Foundation, Palo Alto, CA, ⁶Clinical Evidence and Outcomes, AbbVie, North Chicago, IL
Background/Purpose: Despite guidelines and evidence indicating that early diagnosis and treatment of PsA is critical, few studies have described referral and care-management patterns in a…
Abstract Number: 1242 • 2015 ACR/ARHP Annual Meeting
Germ Line DNA Methylation Profiling Provides Novel Insights into the Parent-of-Origin Effect in Psoriatic Disease
Remy Pollock¹, Darren O'Reilly², Proton Rahman³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Parent-of-origin effects refer to the differential risk or pathogenicity of a disease that depends on the sex of the disease-transmitting parent. Excessive paternal transmission…
Abstract Number: 1692 • 2015 ACR/ARHP Annual Meeting
Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Christopher T. Ritchlin¹, Alice B. Gottlieb², Alan Menter³, Philip J. Mease⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, G James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor University Medical Center, Dallsa, TX, ⁴Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: To describe the rates of serious infections in psoriasis patients with psoriatic arthritis(PsA) from PSOLAR. Methods: PSOLAR is an international, disease-based, observational study in…
Abstract Number: 1694 • 2015 ACR/ARHP Annual Meeting
All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Philip J. Mease¹, Alice B. Gottlieb², Alan Menter³, Christopher T. Ritchlin⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor Research Institute, Dallas, TX, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Describe characteristics and incidence rates of all-cause mortality and malignancies (excluding NMSC) in psoriasis pts with psoriatic arthritis (PsA) from PSOLAR. Methods: PSOLAR is…
Abstract Number: 1589 • 2014 ACR/ARHP Annual Meeting
Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis/Psoriatic arthritis (PsO/PsA) often requires treatment with systemic agents. Some of these agents are associated with infectious adverse events. Few studies have described the…
Abstract Number: 1600 • 2014 ACR/ARHP Annual Meeting
Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities?
Rodolfo Perez Alamino¹, Raquel Cuchacovich², Arnold Zea³ and Luis R. Espinoza⁴, ¹internal Medicine, LSUHSC, New Orleans, LA, ²Rheumatology, LSU Medical Center, New Orleans, LA, ³Stanley Scott Cancer Center, New Orleans, LA, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA
Background/Purpose . New data has emerged about the role of the inflammasome in psoriasis and psoriatic arthritis (PsA). The assembly of the inflammasome components in…
Abstract Number: 1563 • 2014 ACR/ARHP Annual Meeting
Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
David Fiorentino¹, Mark Lebwohl², Vincent Ho³, Richard Langley⁴, Kavitha Goyal⁵, Steve Fakharzadeh⁶, Steve Calabro⁵ and Wayne Langholff⁷, ¹Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Mount Sinai Medical Center, New York, NY, ³University of British Columbia, Vancouver, BC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Janssen Services, LLC, Horsham, PA, ⁶Janssen Services, LLC, Spring House, PA, ⁷Janssen Research and Development, LLC, Spring House, PA
Background/Purpose To report the cumulative incidence of malignancies excluding non-melanoma skin cancers (NMSC) in the PSOLAR study. Methods PSOLAR is a multicenter, longitudinal, observational study…
Abstract Number: 1569 • 2014 ACR/ARHP Annual Meeting
Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry
Alan Menter¹, Kim Papp², Gerald G. Krueger³, Matthias Augustin⁴, Francisco Kerdel⁵, Melinda Gooderham⁶, Kavitha Goyal⁷, Steve Fakharzadeh⁸, Wayne Langholff⁹, Jan Sermon¹⁰, Steve Calabro⁷ and David Pariser¹¹, ¹Baylor Research Institute, Dallas, TX, ²Probity Medical Research, Waterloo, ON, Canada, ³Dermatology, University of Utah, Salt Lake City, UT, ⁴University Clinics of Hamburg, Hamburg, Germany, ⁵University of Miami, Miami, FL, ⁶SKiN Centre for Dermatology, Peterborough, ON, Canada, ⁷Janssen Services, LLC, Horsham, PA, ⁸Janssen Services, LLC, Spring House, PA, ⁹Janssen Research and Development, LLC, Spring House, PA, ¹⁰Janssen-Cilag, Beerse, Belgium, ¹¹Eastern Virginia Medical School and Virginia Clinical Research, Inc, Norfolk, VA
Background/Purpose We evaluated persistency (treatment longevity) of biologics in patients (pts) with psoriasis (PsO), as well as with psoriatic arthritis (PsA) in the context of…
Abstract Number: 1546 • 2014 ACR/ARHP Annual Meeting
Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients
Huifeng Yun¹, Kevin L. Winthrop², Lang Chen³, Wilson Smith⁴, Benjamin Chan⁵, Fenglong Xie⁶, Allison Taylor⁴, Ronac Mamtani⁷, Frank I Scott⁷, James D. Lewis⁸ and Jeffrey R. Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Oregon Health and Science University, Portland, OR, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many systemic treatments for psoriatic arthritis and psoriasis (PsA/PsO) are immune-modulating, which may increase the risk of non-melanoma skin cancer (NMSC). However, the comparative…
Abstract Number: 1562 • 2014 ACR/ARHP Annual Meeting
Psoriasis Longitudinal Assessment and Registry: Global Update upon Full Enrollment
Bruce Strober¹, Alan Menter², Craig Leonardi³, Lyn Guenther⁴, Kavitha Goyal⁵, Wayne Langholff⁶, Steve Calabro⁵ and Steve Fakharzadeh⁷, ¹University of Connecticut Heatlh Center, Farmington, CT, ²Baylor Research Institute, Dallas, TX, ³Central Dermatology, St. Louis, MO, ⁴The Guenther Dermatology Research Centre, London, ON, Canada, ⁵Janssen Services, LLC, Horsham, PA, ⁶Janssen Research and Development, LLC, Spring House, PA, ⁷Janssen Services, LLC, Spring House, PA
Background/Purpose To report the baseline demographics and clinical characteristics of participants enrolled in the Psoriasis Longtitudinal Assessment and Registry (PSOLAR) study. Methods PSOLAR is a…
Abstract Number: 1184 • 2014 ACR/ARHP Annual Meeting
Subclinical Inflammation in Psoriatic Patients with No History of Psoriatic Arthritis: An Assessment By Magnetic Resonance Imaging
David Simon¹, Francesca Faustini¹, Matthias Englbrecht¹, Arnd Kleyer¹, Roland Kocijan², Judith Haschka³, Sebastian Kraus³, Axel J. Hueber¹, Michael Sticherling⁴, Georg Schett¹ and Jürgen Rech³, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Medical Department II, St. Vincent Hospital, Vienna, Austria, ³Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Dermatology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose Six to 39% of patients with cutaneous psoriasis (PSO) can develop psoriatic arthritis (PsA). The transition from skin disease to joint involvement is only…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].